Literature DB >> 21431280

Factors influencing the detection of the BRAF T1799A mutation in papillary thyroid carcinoma.

Hye Soo Kim1, Jong Ok Kim, Dong Ho Lee, Han Chul Lee, Hee Jin Kim, Jeong Hwan Kim, Yi Sun Jang, Jong Min Lee, Seon Young Kim, Yong Sung Kim.   

Abstract

The BRAF T1799A mutation is a heterozygous point mutation and its reported prevalence in papillary thyroid carcinoma (PTC) has varied from 29 to 83%, with an overall mean of 44%. In Korea, the reported mutation rate reached 83% in PTC and 52% in micropapillary carcinoma. We hypothesized that the differences in prevalence may be influenced by the methods of mutation analysis, the sizes of tumor and ethnic differences. Three types of DNA samples from the same PTC mass (0.4-1.6 cm, mean 0.83 cm sized) per each patient (n=17) were isolated. The first type was obtained from frozen PTC tissues using laser-captured microdissection (Frozen-laser, n=17), the second was obtained from frozen tissue by manual tumor margin dissection using a blade (Frozen-blade, n=17) and the third was obtained from formalin-fixed, paraffin-embedded tissue by manual margin dissection (Paraffin-blade, n=15, 2 failed). The mutation rates of the three-matched DNA samples were compared by the SNP mode and AQ mode of pyrosequencing, and direct DNA sequencing. Both the AQ mode of pyrosequencing and the direct DNA sequencing detected the BRAF T1799A mutation in 100% of the 'Frozen-laser' samples, but the mutation was omitted in 1/17 of the 'Frozen-blade' samples and in 5/15 of the 'Paraffin-blade' samples, while the former was more rapid and objective than the latter. The SNP mode of pyrosequencing variably detected the mutation from 40 to 100%, and it showed the lowest sensitivity. Our results indicate that the reported prevalence of the BRAF T1799A mutation in PTC can be underestimated due the mutation analysis methods, and especially in small PTCs. The BRAF T1799A mutation may be an early and essential carcinogenic event in nearly all Korean PTCs, and even in micro-PTCs. For the accurate detection of the BRAF T1799A mutation from small PTCs, fresh or frozen tissues and more cautious microdissection are required, and the AQ mode of pyrosequencing assay is preferred.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21431280     DOI: 10.3892/or.2011.1225

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  3 in total

1.  VE1 immunohistochemical detection of the BRAF V600E mutation in thyroid carcinoma: a review of its usefulness and limitations.

Authors:  Jong-In Na; Jo-Heon Kim; Hye-Jeong Kim; Hee-Kyung Kim; Kyung-Sub Moon; Ji-Shin Lee; Jae-Hyuk Lee; Kyung-Hwa Lee; Jong-Tae Park
Journal:  Virchows Arch       Date:  2015-04-19       Impact factor: 4.064

2.  A more sensitive platform for the detection of low-abundance BRAF(V⁶⁰⁰E) mutations.

Authors:  Weiqin Jiang; Weibin Wang; Fangfang Fu; Xiaodong Teng; Haohao Wang; Haiyong Wang; Lisong Teng
Journal:  Mol Cell Biochem       Date:  2012-03-15       Impact factor: 3.396

3.  Clinical utility of immunohistochemistry for the detection of the BRAF v600e mutation in papillary thyroid carcinoma.

Authors:  Jonathan Zagzag; Aron Pollack; Linda Dultz; Shumon Dhar; Jennifer B Ogilvie; Keith S Heller; Fang-Ming Deng; Kepal N Patel
Journal:  Surgery       Date:  2013-08-06       Impact factor: 3.982

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.